Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment
Oncology·MeSH: Colorectal Neoplasms
Prevalence
135.0 / 100K
Incidence
36.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment?
There are 1 clinical trial targeting Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment tracked by BioSniper.
What is the prevalence of Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment?
The estimated prevalence of Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment is approximately 135.0 per 100,000 population.
Deep-dive into Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis